Inside the research
Fortrea Holdings Inc.
FTRE Research profile · latest available data
Price overview
$19.89
▼ -0.13 (-0.6%)
| 52w hi | $20.70 |
|---|---|
| 52w lo | $8.40 |
| Vol | 708.90K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.04
| Short | +0.27 |
|---|---|
| Medium | +0.11 |
| Long | -0.54 |
computed 2026-09-27
Key fundamentals
Fortrea Holdings Inc.
Healthcare · Biotechnology
| Market cap | $1.89B |
|---|---|
| Enterprise value | $2.84B |
| Forward P/E | 17.47x |
| EV / EBITDA | 28.90x |
| P / S (ttm) | 0.71x |
| Profit margin | -3.2% |
| Return on equity | -15.3% |
| Revenue growth | -4.5% |
| Debt / equity | 213.24 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.11 | |
| Sector | +0.08 | |
| Technical | +0.15 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Risk Metrics
| Beta vs SPX | 1.83 |
|---|---|
| Corr SPX | 0.35 |
| Annual vol | 83.0% |
| Annual ret | +24.8% |
| Sharpe | 0.30 |
| Max DD | -82.9% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Earnings Release, Officer / Director Change… | read |
| 2026-07-14 | Officer / Director Change | read |
| 2026-06-26 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-12 | Shareholder Vote | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-11-20 | Reg FD Disclosure | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-09-22 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-08-27 | Officer / Director Change | read |
| 2025-08-06 | Earnings Release, Exhibits | read |
| 2025-06-12 | Officer / Director Change, Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Thakral Anshul | Chief Executive Officer | Sell | 55.88K | $1.02M |
| 2026-08-06 | Thakral Anshul | Chief Executive Officer | Sell | 55.98K | $1.01M |
| 2026-08-05 | Thakral Anshul | Chief Executive Officer | Sell | 49.45K | $941.07K |
| 2026-08-05 | Thakral Anshul | Chief Executive Officer | Sell | 50.42K | $972.04K |
| 2026-08-04 | Thakral Anshul | Chief Executive Officer | Option exercise | 416.67K | — |
| 2026-08-03 | SANDERS MACHELLE | Sell | 9.70K | $174.70K | |
| 2026-07-20 | Smith David Ross | Option exercise | 6.60K | — | |
| 2026-06-10 | SANDERS MACHELLE | Option exercise | 38.82K | — | |
| 2026-06-10 | Smith David Ross | Option exercise | 38.82K | — | |
| 2026-06-10 | Smith David Ross | Withheld for tax | 18.24K | $298.11K |
Flow & Concentration
| Insider 180d net | -$4.19M |
|---|---|
| Insider buys / sells | 0 / 6 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 93.1% |
| HHI | 2,125 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $65.84M | 3.78M |
| Fidelity / FMR LLC | $63.46M | 3.65M |
| AQR Capital Management | $51.86M | 2.98M |
| Renaissance Technologies | $22.44M | 1.29M |
| Citadel Advisors | $17.80M | 1.02M |
| Millennium Management | $10.90M | 626.49K |
| Capital Research / Capital World | $5.50M | 316.23K |
| T. Rowe Price Group | $2.64K | 151.85K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2023–2025 · 3 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.70B | -6.9% | |
| Operating income | -$872.60M | +196.5% | |
| Net income | -$328.50M | — | |
| Cash from ops | $262.80M | +73.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $19.90 | $20.28 | $19.35 | $19.89 | 708.90K |
| Sep 24 | $19.40 | $20.49 | $19.25 | $20.02 | 1.23M |
| Sep 23 | $20.25 | $20.71 | $19.50 | $19.52 | 1.07M |
| Sep 22 | $20.13 | $20.58 | $20.13 | $20.43 | 1.51M |
| Sep 21 | $20.29 | $20.44 | $19.67 | $20.02 | 1.05M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →